纳武单抗联合阿托伐他汀三线及以上方案治疗转移性肾细胞癌患者的临床疗效及其预后影响因素研究

Clinical efficacy of third-and later-line regimen of nivolumab plus statins in the treatment of patients with metastatic renal cell carcinoma and their prognosis factors

目的探讨纳武单抗联合阿托伐他汀三线及以上方案治疗转移性肾细胞癌(metastatic renal cell carcinoma,mRCC)的临床疗效。方法通过回顾性的收集2018年1月—2022年12月在永州市中心医院泌尿外科和肿瘤内科临床二线治疗失败的137例mRCC患者。mRCC患者根据治疗方案分为纳武单抗单药治疗组(single treatment group,STG)和纳武单抗+阿托伐他汀联合治疗组(combined treatment group,CTG)。对所有患者的客观反应率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、无进展生存期(progression-free survival,PFS)和总生存期(overall survival,OS)进行评估。采用Kaplan-Meier法和log-rank检验对生存资料进行分析。此外,单因素和多因素Cox风险比例回归探讨不同临床特征对PFS和OS的影响。结果本研究共纳入137例mRCC患者,其中CTG 46例,STG 91例。CTG和STG的ORR分别为28.26%和20.88%,DCR分别为56.52%和37.36%。CTG的中位PFS和中位OS均高于STG(8.92个月vs 6.80个月,P<0.05;24.22个月vs 10.63个月,P<0.05)。既往未行肾切除、≥2个转移部位和三线以上治疗方案是mRCC患者中位PFS的独立危险因素。而既往未行肾切除和三线以上治疗方案是mRCC患者中位OS的独立危险因素。结论纳武单抗联合他汀类药物三线及以上方案治疗mRCC明显优于纳武单抗单药治疗,可显著延长mRCC患者的PFS和OS。有待进一步的前瞻性临床试验验证。

Objective To evaluate the clinical efficacy of nivolumab plus atorvastatin as a third-or later-line treatment for patients with metastatic renal cell carcinoma(mRCC).Methods A total of 137 patients with mRCC who were histopathologically confirmed and failed in clinical second-line therapy regimens at Yongzhou Center Hospital from January 2018 to December 2022 were retrospectively selected.Patients with mRCC were divided into the single treatment group(STG)of nivolumab monotherapy,and the combined treatment group(CTG)of nivolumab in combination with atorvastatin.The primary outcomes of interest were objective response rate(ORR)and disease control rate(DCR),progression-free survival(PFS),and overall survival(OS).Survival data were analyzed using the Kaplan-Meier method,and the log-rank test was performed.Additionally,Cox proportional hazard regression was used to explore the effect of different clinical features on PFS and OS.Results Of the 137 patients with mRCC included in the research,91 patients received nivolumab,and 46 patients received nivolumab plus atorvastatin.The ORR of CTG and STG were 28.26%and 20.88%,and the DCR were 56.52%and 37.36%,respectively.The median PFS(mPFS)and median OS(mOS)in CTG were higher than those in the STG(8.92 months vs 6.80 months,P<0.05;24.22 months vs 10.63 months,P<0.05;respectively).No previous nephrectomy,more than two metastatic sites,and>third-line treatment were independent risk factors for the mPFS of patients with mRCC,and no previous nephrectomy and>third-line treatment were independent risk factors for the mOS of patients with mRCC.Conclusion Nivolumab combined with atorvastatin as the third-or later-line regimen greatly prolonged PFS and OS of mRCC patients.A prospective clinical trial is warranted.